Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.

Goldman, JW; Garassino, MC; Chen, Y; Özgüroğlu, MUSTAFA; Dvorkin, M; Trukhin, D; Statsenko, G; Hotta, K; Ji, JH; Hochmair, MJ; Voitko, O; Havel, L; Poltoratskiy, A; Losonczy, G; Reinmuth, N; Patel, N; Laud, PJ; Shire, N; Jiang, H; Paz-Ares, L

doi:10.1016/j.lungcan.2020.09.003

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.

Goldman J., Garassino M., Chen Y., Özgüroğlu M., Dvorkin M., Trukhin D., ...Daha Fazla

Lung cancer (Amsterdam, Netherlands), cilt.149, ss.46-52, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 149
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.lungcan.2020.09.003
Dergi Adı: Lung cancer (Amsterdam, Netherlands)
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
Sayfa Sayıları: ss.46-52
Anahtar Kelimeler: Small-cell lung cancer, Durvalumab, Platinum-etoposide, CASPIAN, Patient-reported outcomes, Health-related quality of life, QUALITY-OF-LIFE, AMERICAN-COLLEGE, ONCOLOGY, QLQ-C30
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Objectives: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) at the interim analysis. Here we report patient-reported outcomes (PROs).